Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.

TRDA

Entrada Therapeutics (TRDA)

Entrada Therapeutics Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:TRDA
FechaHoraFuenteTítuloSímboloCompañía
20/05/202416:26Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TRDAEntrada Therapeutics Inc
16/05/202415:18Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:TRDAEntrada Therapeutics Inc
16/05/202406:00GlobeNewswire Inc.Entrada Therapeutics to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQNASDAQ:TRDAEntrada Therapeutics Inc
07/05/202406:10Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:TRDAEntrada Therapeutics Inc
07/05/202406:04Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TRDAEntrada Therapeutics Inc
07/05/202406:00GlobeNewswire Inc.Entrada Therapeutics Reports First Quarter 2024 Financial ResultsNASDAQ:TRDAEntrada Therapeutics Inc
13/03/202406:00GlobeNewswire Inc.Entrada Therapeutics Reports Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:TRDAEntrada Therapeutics Inc
07/02/202406:00GlobeNewswire Inc.Entrada Therapeutics to Present at Upcoming Investor ConferencesNASDAQ:TRDAEntrada Therapeutics Inc
03/01/202406:00GlobeNewswire Inc.Entrada Therapeutics Promotes Nathan J. Dowden to PresidentNASDAQ:TRDAEntrada Therapeutics Inc
22/11/202310:56Dow Jones NewsEntrada Therapeutics Shares Tumble 27% After FDA Keeps Clinical HoldNASDAQ:TRDAEntrada Therapeutics Inc
22/11/202306:54Dow Jones NewsEntrada: FDA Declines to Lift Hold on Duchenne StudyNASDAQ:TRDAEntrada Therapeutics Inc
22/11/202306:00GlobeNewswire Inc.Entrada Therapeutics Announces Updates on ENTR-601-44 in Duchenne Muscular DystrophyNASDAQ:TRDAEntrada Therapeutics Inc
07/11/202306:00GlobeNewswire Inc.Entrada Therapeutics Reports Third Quarter 2023 Financial ResultsNASDAQ:TRDAEntrada Therapeutics Inc
29/09/202315:35Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:TRDAEntrada Therapeutics Inc
21/09/202306:00GlobeNewswire Inc.Entrada Therapeutics Announces First Participant Dosed in its Phase 1 Clinical Trial of ENTR-601-44 for the Potential Treatment of Duchenne Muscular DystrophyNASDAQ:TRDAEntrada Therapeutics Inc
07/09/202306:00GlobeNewswire Inc.Entrada Therapeutics Awards Funding to Non-Profit Organizations Advancing Diversity, Equity, Inclusion and Accessibility within the Duchenne Muscular Dystrophy CommunityNASDAQ:TRDAEntrada Therapeutics Inc
05/09/202315:29Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:TRDAEntrada Therapeutics Inc
10/08/202306:00GlobeNewswire Inc.Entrada Therapeutics Appoints Gina Chapman to its Board of DirectorsNASDAQ:TRDAEntrada Therapeutics Inc
08/08/202306:25Edgar (US Regulatory)Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend]NASDAQ:TRDAEntrada Therapeutics Inc
08/08/202306:23Edgar (US Regulatory)Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]NASDAQ:TRDAEntrada Therapeutics Inc
08/08/202306:00GlobeNewswire Inc.Entrada Therapeutics Reports Second Quarter 2023 Financial ResultsNASDAQ:TRDAEntrada Therapeutics Inc
01/08/202306:00GlobeNewswire Inc.Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate Phase 1 Clinical Trial of ENTR-601-44 for the Potential Treatment of Duchenne Muscular DystrophyNASDAQ:TRDAEntrada Therapeutics Inc
22/06/202315:46Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:TRDAEntrada Therapeutics Inc
22/06/202315:13Edgar (US Regulatory)Report of Proposed Sale of Securities (144)NASDAQ:TRDAEntrada Therapeutics Inc
08/06/202316:12Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:TRDAEntrada Therapeutics Inc
06/06/202306:00GlobeNewswire Inc.Entrada Therapeutics to Present at Goldman Sachs 44th Annual Global Healthcare ConferenceNASDAQ:TRDAEntrada Therapeutics Inc
10/05/202306:46Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:TRDAEntrada Therapeutics Inc
10/05/202306:00GlobeNewswire Inc.Entrada Therapeutics Reports First Quarter 2023 Financial ResultsNASDAQ:TRDAEntrada Therapeutics Inc
25/04/202306:04Edgar (US Regulatory)Annual Report to Security Holders (ars)NASDAQ:TRDAEntrada Therapeutics Inc
25/04/202306:02Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:TRDAEntrada Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:TRDA